Palbociclib
- Generic Name
- Palbociclib
- Brand Names
- Ibrance
- Drug Type
- Small Molecule
- Chemical Formula
- C24H29N7O2
- CAS Number
- 571190-30-2
- Unique Ingredient Identifier
- G9ZF61LE7G
- Background
Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties.
...
- Indication
Palbociclib is indicated in combination with letrozole as initial endocrine-based therapy for the treatment of human epidermal growth factor receptor type 2 (HER2)-negative and hormone receptor(HR)-positive tumors in adult patients with advanced/metastatic breast cancer. It is as well approved in combination with fulvestrant in patients with disease progress...
- Associated Conditions
- Advanced Breast Cancer, Metastatic Breast Cancer, Refractory, advanced Breast cancer, Refractory, metastatic Breast cancer
- Associated Therapies
- -
Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate
- Conditions
- First Posted Date
- 2014-05-20
- Last Posted Date
- 2018-12-21
- Lead Sponsor
- Pfizer
- Registration Number
- NCT02142868
- Locations
- 🇺🇸
Presence Saint Joseph Hospital, Chicago, Illinois, United States
🇺🇸Presence Infusion Care - Skokie, Skokie, Illinois, United States
🇺🇸SKCCC at Johns Hopkins, The Harry and Jeannette Weinberg Building, Baltimore, Maryland, United States
Study Of Palbociclib (PD-0332991) In Renal Impairment
- First Posted Date
- 2014-03-13
- Last Posted Date
- 2018-04-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 31
- Registration Number
- NCT02085538
- Locations
- 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸Avail Clinical Research, LLC, DeLand, Florida, United States
🇺🇸Prism Research, Saint Paul, Minnesota, United States
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors
- First Posted Date
- 2014-02-17
- Last Posted Date
- 2018-06-01
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 28
- Registration Number
- NCT02065063
- Locations
- 🇺🇸
GSK Investigational Site, Houston, Texas, United States
A Study To Investigate Palbociclib (PD-0332991) Pharmacokinetics In Healthy Subjects Of Japanese Descent Relative To Healthy Non-Asian Subjects, And To Determine If Changes In Palbociclib Dose Result In Proportional Changes In Palbociclib Plasma Exposure In Japanese Subjects
- Conditions
- Interventions
- First Posted Date
- 2014-02-11
- Last Posted Date
- 2014-06-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 27
- Registration Number
- NCT02059330
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States
Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer
- First Posted Date
- 2014-01-20
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 162
- Registration Number
- NCT02040857
- Locations
- 🇺🇸
MGH/North Shore Cancer Center, Danvers, Massachusetts, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
🇺🇸South Shore Hospital, Weymouth, Massachusetts, United States
Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2014-01-08
- Last Posted Date
- 2018-08-22
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 9
- Registration Number
- NCT02030483
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors
- Conditions
- Interventions
- First Posted Date
- 2014-01-07
- Last Posted Date
- 2021-01-20
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 693
- Registration Number
- NCT02028507
- Locations
- 🇮🇱
Sheba Medical Center, Tel Hashomer, Israel
🇦🇹Universitätsklinik für Innere Medizin III, Salzburg, Austria
🇦🇹Landes-Krankenhaus Steyr, Steyr, Austria
PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2013-12-30
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 60
- Registration Number
- NCT02022982
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
A Study To Investigate The Drug-Drug Interaction Potential Of Rifampin OnThe Investigational Agent Palbociclib (PD-0332991)
- First Posted Date
- 2013-10-01
- Last Posted Date
- 2014-01-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 15
- Registration Number
- NCT01953731
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States
Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)
- Conditions
- Interventions
- First Posted Date
- 2013-09-13
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 521
- Registration Number
- NCT01942135
- Locations
- 🇺🇸
Holy Cross Hospital/Michael and Dianne Bienes Comprehensive Cancer Center, Fort Lauderdale, Florida, United States
🇺🇸Sylvester Comprehensive Cancer Center Deerfield Beach, Deerfield Beach, Florida, United States
🇺🇸Memorial Cancer Institute at Memorial Hospital West, Pembroke Pines, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.